Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Published: February 2011

Open Access Gateway

Pure Small Cell Carcinoma of the Prostate: A Case Report and Literature Review

Capizzello A.a · Peponi E.a · Simou N.b · Ntaskagiannis D.a · Tasiou I.a · Kamina S.b · Tsekeris P.a

Author affiliations

aRadiation Therapy Department and bPathology Department, University Hospital of Ioannina, Ioannina, Greece

Corresponding Author

Evangelia Peponi

Radiation Therapy Department, University Hospital of Ioannina

L. Staurou Niarxou, GR–45500 Ioannina (Greece)

Tel. +30 697 432 7692, E-Mail vagelita@yahoo.com

Related Articles for ""

Case Rep Oncol 2011;4:88–95

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Primary small cell carcinoma of the prostate (SCPCa) is a rare pathologic entity with unique clinical features and a poor prognosis. We present a case of a patient diagnosed with pure SCPCa treated with a combined chemo-radiotherapeutic approach. Pathological findings showed that the neoplastic cells exhibited positivity for pancytokeratin, synaptophysin, thyroid transcription factor-1 and CD56. Immunostaining for prostate-specific antigen was negative, while serum prostate-specific antigen was within normal limits. We review the available literature to gain additional information about diagnosis, treatment and prognosis of pure SCPCa.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: February 2011

Published online: February 16, 2011
Issue release date: January – April

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 1

eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.